ABVC BioPharma, Inc. (ABVC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 1 | 0 | 1 | 0 | -1 | - |
| Operating profit | $m | -7 | -7 | ||||||
| Net profit | $m | -10 | -13 | -16 | -8 | -5 | -8 | -8 | - |
| EPS reported | $ | -0.39 | -0.29 | ||||||
| Operating cashflow per share | $ | -0.13 | -0.10 | ||||||
| Capex per share | $ | 0.00 | 0.01 | ||||||
| FCF per share | $ | -0.13 | -0.09 | ||||||
| Free cash flow | $m | -3 | -2 | ||||||
| Net debt | $m | 3 | -0 | ||||||
| Book value equity | $m | 11 | 10 | ||||||
| Book value per share | $ | 0.48 | 0.39 | ||||||
| Number of shares | m | 23.26 | 26.06 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 4.46 | 4.82 | ||||||
| P/S LTM | x | 0.00 | -62.24 | ||||||
| P/FCF LTM | x | -16.59 | -20.25 | ||||||
| EV/EBITDA LTM | x | -7.04 | -6.69 | ||||||
| EV/Sales LTM | x | 0.00 | -33.54 | ||||||
| Earnings Yield LTM | % | -15.97% | -31.59% | ||||||
| FCF Yield | % | -6.03% | -4.94% | ||||||
| Quality | |||||||||
| ROE | % | -71.17% | -71.47% | ||||||
| ROIC | % | -42.64% | -51.98% | ||||||
| Operating margin | % | 0.00% | +9.19% | ||||||
| Gross margin | % | 0.00% | +100.00% | ||||||
| FCF/Sales | % | - | +307.37% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -100.00% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.86 | -1.39 | ||||||
| Net Debt/EBITDA | x | -0.38 | -0.22 | ||||||
| EBIT/Net interest | x | -17.20 | -47.11 | ||||||
| Net debt/market cap | % | +7.01% | 0.00% | ||||||
| Net debt/Equity | x | 0.25 | -0.01 | ||||||
| Gross debt/equity | x | 0.31 | 0.17 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free